Company
Poolbeg Pharma PLC
Headquarters: London, United Kingdom
CEO: Dr. Jeremy Skillington Ph.D.
Poolbeg Pharma PLC Categories
United Kingdom Healthcare BiotechnologyUnited Kingdom Healthcare United Kingdom Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $121.36 B |
| Regeneron Pharmaceuticals, Inc. | $115.11 B |
| CSL Limited | $95.75 B |
| Marinomed Biotech AG | $75.67 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Detailed Description
Poolbeg Pharma PLC operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. Its products include POLB 001, a Phase-II ready p38 MAP Kinase inhibitor that reduces harmful inflammation in patients with severe forms of influenza; PredictViral Biomarker Platform, a tool for predicting severe diseases; and vaccine discovery platform, which are techniques used in human challenge models to identify vaccine candidates that drive preferential T-Cell immune responses. The company was formerly known as Orph Pharma Limited and changed its name to Poolbeg Pharma PLC in June 2021. Poolbeg Pharma PLC was incorporated in 2021 and is headquartered in London, the United Kingdom.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
Poolbeg Pharma PLC has the following listings and related stock indices.
Stock: LSE: POLB wb_incandescent